ClinicalTrials.govpublic full text
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
acute myeloid leukemia, acute lymphoblastic leukemia, mds, transplantation, stem cell, conditioning therapy, shr2554, azacytidine, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 877946
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.